Natera initiated at Buy with $435 target, citing MRD market leadership

UBS initiated coverage on Natera with a Buy rating.

The bank established a price target of $435 for the stock. Analysts identified Natera as a leader in the large and growing minimal residual disease (MRD) market. UBS also highlighted the company’s profitable prenatal business and expanding oncology platform.

The $435 target suggests significant upside from current trading levels. This follows Rothschild & Co Redburn recently starting coverage with a Buy rating.

Redburn set a $385 price target based on the strength of Natera’s Signatera test. Wall Street analysts currently maintain a Strong Buy consensus for the company.